ArticleRespiratory research2011
Genetic variation in TIMP1 but not MMPs predict excess FEV1 decline in two general population-based cohorts.
Article in Respiratory research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Genetic polymorphism of matrix metalloproteinase family and chronic obstructive pulmonary disease susceptibility: a meta-analysis.Scientific reports · 2013Pooled it
- Tissue inhibitor of metalloproteinase 1 promotes ferroptosis and suppresses prostate cancer metastasis.The Journal of biological chemistry · 2025Article
- Association of theArchives of medical science : AMS · 2024Review
- Haplotype inInternational journal of molecular sciences · 2019Article
- The role of MMP-12 gene polymorphism - 82 A-to-G (rs2276109) in immunopathology of COPD in polish patients: a case control study.BMC medical genetics · 2019Article
- Polymorphisms in MMP-14 and MMP-2 genes and ovarian cancer survival.Cancer biomarkers : section A of Disease markers · 2019Article
- MMP-2 (-1306 C/T) Polymorphism Affects Serum Matrix Metalloproteinase (MMP)-2 Levels and Correlates with Chronic Obstructive Pulmonary Disease Severity: A Case-Control Study of MMP-1 and -2 in a Tunisian Population.Molecular diagnosis & therapy · 2016Article
- MMP-1 and -3 promoter variants are indicative of a common susceptibility for skin and lung aging: results from a cohort of elderly women (SALIA).The Journal of investigative dermatology · 2015Article
- Frequency of the common promoter polymorphismBiotechnology, biotechnological equipment · 2015Article
- Joint modelling of repeated measurements and time-to-event outcomes: flexible model specification and exact likelihood inference.Journal of the Royal Statistical Society. Series B, Statistical methodology · 2015Article
- Relationships of COX2 and MMP12 genetic polymorphisms with chronic obstructive pulmonary disease risk: a meta-analysis.Molecular biology reports · 2014Article
- The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis.Critical care (London, England) · 2013Observational
- Genomics of Chronic Obstructive Pulmonary Disease (COPD); Exploring the SNPs of Protease-Antiprotease Pathway.Current genomics · 2013Article
- Genome-wide study identifies two loci associated with lung function decline in mild to moderate COPD.Human genetics · 2013Article
- Specific IgA and metalloproteinase activity in bronchial secretions from stable chronic obstructive pulmonary disease patients colonized by Haemophilus influenzae.Respiratory research · 2012Article
- Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study.Thorax · 2012Article
- Heterozygosity for E292V in ABCA3, lung function and COPD in 64,000 individuals.Respiratory research · 2012Article
- Updates on the COPD gene list.International journal of chronic obstructive pulmonary disease · 2012Review
- The α(1)AT and TIMP-1 Gene Polymorphism in the Development of Asthma.Comparative and functional genomics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn imbalance in matrix metalloproteases (MMPs) and tissue inhibitors of MMPs (TIMPs) contributes to chronic obstructive pulmonary disease (COPD) development. Longitudinal studies investigating Single Nucleotide Polymorphisms (SNPs) in MMPs and TIMPs with respect to COPD development and lung function decline in the general population are lacking.
methodsWe genotyped SNPs in MMP1 (G-1607GG), MMP2 (-1306 C/T), MMP9 (3 tagging SNPs), MMP12 (A-82G and Asn357Ser) and TIMP1 (Phe124Phe and Ile158Ile) in 1390 Caucasians with multiple FEV1 measurements from a prospective cohort study in the general population. FEV1 decline was analyzed using linear mixed effect models adjusted for confounders. Analyses of the X-chromosomal TIMP1 gene were stratified according to sex. All significant associations were repeated in an independent general population cohort (n=1152).
resultsMMP2 -1306 TT genotype carriers had excess FEV1 decline (-4.0 ml/yr, p=0.03) compared to wild type carriers. TIMP1 Ile158Ile predicted significant excess FEV1 decline in both males and females. TIMP1 Phe124Phe predicted significant excess FEV1 decline in males only, which was replicated (p=0.10) in the second cohort. The MMP2 and TIMP1 Ile158Ile associations were not replicated. Although power was limited, we did not find associations with COPD development.
conclusionsWe for the first time show that TIMP1 Phe124Phe contributes to excess FEV1 decline in two independent prospective cohorts, albeit not quite reaching conventional statistical significance in the replication cohort. SNPs in MMPs evidently do not contribute to FEV1 decline in the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.